24/7 Market News Snapshot 20 March, 2025 – ARS Pharmaceuticals, Inc. Common Stock (NASDAQ:SPRY)

March 20, 2025

DENVER, Colo., 20 March, 2025 (247marketnews.com) – (NASDAQ:SPRY) are discussed in this article.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is experiencing significant momentum, with its stock price rising from a previous close of $11.650 to $14.159 today, marking an impressive increase of 21.54%. The heightened trading activity, with a volume of 2.09 million shares, reflects strong investor confidence and market enthusiasm for the biopharmaceutical sector, particularly following the launch of its innovative product, neffy® (epinephrine nasal spray).

Neffy, designed for the emergency treatment of Type I allergic reactions, including anaphylaxis, was commercially launched in late September 2024. This groundbreaking formulation is critical for individuals, especially children, at risk of severe allergic reactions. Since its release, neffy has generated $7.3 million in U.S. net product revenue, and the recent FDA approval for its use in children ages four and older adds further significance by providing crucial access to approximately 2 million school-aged children susceptible to life-threatening allergies.

Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma, emphasized the company’s dedication to empowering patients and caregivers, citing a robust financial foundation with $314 million in cash and investments, enabling a strong commercialization push in 2025. ARS reported total revenue of $89.1 million for the full year 2024, bolstered by key collaboration agreements that enhance its market presence.

To ensure widespread adoption, ARS Pharma is actively engaging around 9,000 healthcare providers and has secured favorable payer coverage. A comprehensive marketing initiative is scheduled to launch in May 2025, strategically timed to align with heightened epinephrine prescribing seasons. Coupled with plans for pivotal studies and potential international market expansion, ARS Pharma is strategically positioned for continued growth and transformative impacts in allergy treatment.

Related news for (SPRY)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.